Trial Profile
A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation From Living CMV-Seropositive Donors (D+)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Oct 2023
Price :
$35
*
At a glance
- Drugs HB 101 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Pharmacodynamics; Proof of concept
- Sponsors Hookipa Pharma
- 14 Nov 2022 According to a Hookipa Pharma media release, data expected in the first half of 2023.
- 29 Aug 2022 This trial has been completed in Belgium (Global end date is 22 Jun 2022), according to European Clinical Trials Database record.
- 10 Aug 2022 Status changed from active, no longer recruiting to completed.